These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 9717834)

  • 41. Modulation of Ca2+ influx by corticotropin-releasing factor (CRF) family of peptides via CRF receptors in rat pancreatic beta-cells.
    Kageyama K; Kimura R; Suga S; Ogawa Y; Suda T; Wakui M
    Peptides; 2006 Jul; 27(7):1814-9. PubMed ID: 16513211
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Evidence that corticotropin-releasing factor receptor type 1 couples to Gs- and Gi-proteins through different conformations of its J-domain.
    Berger H; Heinrich N; Wietfeld D; Bienert M; Beyermann M
    Br J Pharmacol; 2006 Dec; 149(7):942-7. PubMed ID: 17057757
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Molecular cloning of bullfrog corticotropin-releasing factor (CRF): effect of homologous CRF on the release of TSH from pituitary cells in vitro.
    Ito Y; Okada R; Mochida H; Hayashi H; Yamamoto K; Kikuyama S
    Gen Comp Endocrinol; 2004 Sep; 138(3):218-27. PubMed ID: 15364204
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Identification of two corticotropin-releasing factor receptors from Xenopus laevis with high ligand selectivity: unusual pharmacology of the type 1 receptor.
    Dautzenberg FM; Dietrich K; Palchaudhuri MR; Spiess J
    J Neurochem; 1997 Oct; 69(4):1640-9. PubMed ID: 9326293
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The first extracellular domain of corticotropin releasing factor-R1 contains major binding determinants for urocortin and astressin.
    Perrin MH; Sutton S; Bain DL; Berggren WT; Vale WW
    Endocrinology; 1998 Feb; 139(2):566-70. PubMed ID: 9449626
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Signaling properties of mouse and human corticotropin-releasing factor (CRF) receptors: decreased coupling efficiency of human type II CRF receptor.
    Xiong Y; Xie LY; Abou-Samra AB
    Endocrinology; 1995 May; 136(5):1828-34. PubMed ID: 7720627
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A soluble mouse brain splice variant of type 2alpha corticotropin-releasing factor (CRF) receptor binds ligands and modulates their activity.
    Chen AM; Perrin MH; Digruccio MR; Vaughan JM; Brar BK; Arias CM; Lewis KA; Rivier JE; Sawchenko PE; Vale WW
    Proc Natl Acad Sci U S A; 2005 Feb; 102(7):2620-5. PubMed ID: 15701705
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cloning and characterization of corticotropin-releasing factor and urocortin in Syrian hamster (Mesocricetus auratus).
    Robinson BM; Tellam DJ; Smart D; Mohammad YN; Brennand J; Rivier JE; Lovejoy DA
    Peptides; 1999; 20(10):1177-85. PubMed ID: 10573289
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Conformational states of the corticotropin releasing factor 1 (CRF1) receptor: detection, and pharmacological evaluation by peptide ligands.
    Hoare SR; Sullivan SK; Pahuja A; Ling N; Crowe PD; Grigoriadis DE
    Peptides; 2003 Dec; 24(12):1881-97. PubMed ID: 15127940
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Peptide ligand binding properties of the corticotropin-releasing factor (CRF) type 2 receptor: pharmacology of endogenously expressed receptors, G-protein-coupling sensitivity and determinants of CRF2 receptor selectivity.
    Hoare SR; Sullivan SK; Fan J; Khongsaly K; Grigoriadis DE
    Peptides; 2005 Mar; 26(3):457-70. PubMed ID: 15652653
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Corticotropin releasing factor receptors and their ligand family.
    Perrin MH; Vale WW
    Ann N Y Acad Sci; 1999 Oct; 885():312-28. PubMed ID: 10816663
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Hypothalamic expression of urocortin 3 and the type 2 corticotropin-releasing factor receptor is regulated according to feeding state in lean but not obese Zucker rats.
    Poulin AM; Lenglos C; Mitra A; Timofeeva E
    Neuropharmacology; 2012 Jul; 63(1):147-53. PubMed ID: 22227020
    [TBL] [Abstract][Full Text] [Related]  

  • 53. CRF2 receptors are highly expressed in the human cardiovascular system and their cognate ligands urocortins 2 and 3 are potent vasodilators.
    Wiley KE; Davenport AP
    Br J Pharmacol; 2004 Oct; 143(4):508-14. PubMed ID: 15381637
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Ligand requirements of the human corticotropin-releasing factor-binding protein.
    Sutton SW; Behan DP; Lahrichi SL; Kaiser R; Corrigan A; Lowry P; Potter E; Perrin MH; Rivier J; Vale WW
    Endocrinology; 1995 Mar; 136(3):1097-102. PubMed ID: 7867564
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Neurobiology of corticotropin releasing factor (CRF) receptors and CRF-binding protein: implications for the treatment of CNS disorders.
    Behan DP; Grigoriadis DE; Lovenberg T; Chalmers D; Heinrichs S; Liaw C; De Souza EB
    Mol Psychiatry; 1996 Sep; 1(4):265-77. PubMed ID: 9118350
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Identification of a second corticotropin-releasing factor receptor gene and characterization of a cDNA expressed in heart.
    Perrin M; Donaldson C; Chen R; Blount A; Berggren T; Bilezikjian L; Sawchenko P; Vale W
    Proc Natl Acad Sci U S A; 1995 Mar; 92(7):2969-73. PubMed ID: 7708757
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Corticotropin-releasing factor receptors in human small cell lung carcinoma cells: radioligand binding, second messenger, and northern blot analysis data.
    Dieterich KD; Grigoriadis DE; De Souza EB
    Endocrinology; 1994 Oct; 135(4):1551-8. PubMed ID: 7925116
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Impact of N-terminal domains for corticotropin-releasing factor (CRF) receptor-ligand interactions.
    Klose J; Fechner K; Beyermann M; Krause E; Wendt N; Bienert M; Rudolph R; Rothemund S
    Biochemistry; 2005 Feb; 44(5):1614-23. PubMed ID: 15683245
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Ligand affinity for amino-terminal and juxtamembrane domains of the corticotropin releasing factor type I receptor: regulation by G-protein and nonpeptide antagonists.
    Hoare SR; Sullivan SK; Schwarz DA; Ling N; Vale WW; Crowe PD; Grigoriadis DE
    Biochemistry; 2004 Apr; 43(13):3996-4011. PubMed ID: 15049707
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparison of an agonist, urocortin, and an antagonist, astressin, as radioligands for characterization of corticotropin-releasing factor receptors.
    Perrin MH; Sutton SW; Cervini LA; Rivier JE; Vale WW
    J Pharmacol Exp Ther; 1999 Feb; 288(2):729-34. PubMed ID: 9918582
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.